<h4>Objectives</h4>Febuxostat, an oral medication for treating hyperuricemia (HUA), is a non-purine xanthine oxidase inhibitor that regulates serum uric acid (SUA) metabolism in patients with chronic kidney disease (CKD). This evidence concerns the gene XDH and chronic kidney disease.